BIOTECHNOLOGY

INDUSTRY
VIVEKRAJ S N (10AB45)
SIDDARTH VARSHAN(10AB35)
APARNA V(10AB04)
RANJANA KRISHNAN(10AB26)
SANGEETHA PRIYA U (10AB30)
 INTRODUCTION
 Biotechnology is a field of applied biology that involves the
use of living organisms and bioprocesses in engineering,
technology, medicine and other fields requiring bio-products.
 The United Nations Convention on Biological Diversity
defines biotechnology as:"Any technological application that
uses biological systems, living organisms, or derivatives
thereof, to make or modify products or processes for specific
use."

CONTD…
 Biotechnology draws on the pure biological sciences
 (genetics, microbiology, animal cell culture, molecular biology,
biochemistry, embryology, cell biology)
 also dependent on knowledge and methods from outside the
sphere of biology.
 (chemical engineering, bioprocess engineering, information
technology, biorobotics).

HISTORY OF BIOTECHNOLOGY
 drugs.The good and bad kind !
 malnutrition and famine. Many mouths,
little land !
 Beer is good- drink more- boiotech thanks
you !
 1978- The magic bullet for diabetes.
 80s era- sunshine industry

CONTD…
 In 1988, only 5 proteins from genetically engineered cells had
been approved as drugs by the United States Food and Drug
Administration (FDA), but this number skyrocketed to over
125 by the end of the 1990s.
 While it seems only natural nowadays to link pharmaceutical
drugs as solutions to health and societal problems, this
relationship of biotechnology serving social needs began
centuries ago.
 With ancestral roots in industrial microbiology that date back
centuries, the biotechnology industry grew rapidly beginning
in the mid-1970s.

CONTD…
 Genetic engineering in biotechnology stimulated hopes for
both therapeutic proteins and drugs and biological organisms
themselves, such as seeds, pesticides, engineered yeasts, and
modified human cells for treating genetic diseases.
 From the perspective of its commercial promoters, scientific
breakthroughs, industrial commitment, and official support
were finally coming together, and biotechnology became a
normal part of business.

SWOT Analysis
STRENGTHS
 Highly skilled and qualified scientific manpower
 Government taking initiatives to support biotech sector
 Capability in handling fermentation based compounds,
extraction of high quality products using plant and
animal parts.
 plant breeding techniques, plant cell/tissue culture,
bioprocess engineering, use of cell/microbial culture
techniques, etc
 Effective and efficient biotech enterprises.
 Infrastructure in manufacturing processing equipments
and bio-reactors

WEAKNESS
 Administration of resources supporting biotech research
and development
 Lack of awareness regarding biotech practices
 Missing link between research and commercialisation.
 Lack of venture capital
 Relatively low R&D expenditure by industry
 Image of Indian industry -doubts about ability of Indian
products to meet international standards of quality
OPPURTUNITIES
 Large market
 Export potential
 Base for contract research for international companies
due to rising costs of R&D abroad.
 Large number of patients covering wider range of
diseases
THREATS
 Lack of advanced biotechnologies and products
 Lack of public awareness about biotechnology issues
 Difference between theory and practice in R&D
 Danger of anti-biotech propaganda gaining ground
MAJOR INVESTMENTS
 Panacea Biotec Ltd has bagged a three-year contract worth
over US$ 222.37 million from UNICEF to provide the
agency with EasyFive vaccine, a protection against a set of
pediatric diseases for 2010, 2011 and 2012.
 Alexandria Real Estate, the US$ 5.2 billion US-based company
which provides solutions to life science industry, has decided
to set up a biotech research and development (R&D) and
incubation facility in Gujarat. It plans to spend around US$
107 million for the project.

CONTD…
 The Defence Research and Development Organisation
(DRDO), which caters primarily to the armed forces, plans
to spend US$ 63.5 million to upgrade and custom-make its
existing line of biotech products for civilian use.
 Biotechnology major Biocon has fully acquired the joint
venture Biocon Biopharmaceuticals from its Cuban partner
CIMAB. Under the business restructuring plan, Biocon will
pick up CIMAB's 49 per cent stake and will make Biocon
Biopharmaceuticals (BBPL) a wholly owned subsidiary of
Biocon.

PEST ANALYSIS
POLITICAL
 Commercial cultivation of BT cotton was approved by the
government in early 2002 which today accounts for about 70
per cent of the total area under cotton cultivation and thus
makes agri-biotech the fastest growing biotech industry.
 The government has announced a National Biotechnology
Policy as recognition of the importance of the sector as a key
growth area. The key elements of strategy include:
 (i)Set up of a National Biotechnology Regulatory Authorit
 (ii) A high-powered Inter-ministerial Committee is to be set up
under the chairmanship of secretary, DBT, to effectively
coordinate the development of the sector by addressing cross
cutting issues.
 (iii) 30 percent of DBT's Budget to be spent on public-private
partnership programs.

CONTD…
 (iv) A Biotechnology Industry Partnership Programme (BIPP)
for Advanced Technology would be launched.
 (v) The existing Small Business Innovation Research Industry
(SBIRI) scheme to promote innovation in SMEs has been a
success.
 Biotech Parks: The government has set up exclusive
Biotech Parks such as Shapoorji Pallonji Biotech
Park, Hyderabad; ICICI Knowledge Park, Hyderabad;
International Biotech Park, Pune. These
biotechnology parks are acting as bioclusters - where
companies, universities and R&D institutes are all
located in one place.

ECONOMIC
Market Trends:


 India is ranked among the top 12 biotech destinations in the world and
the Indian biotech sector is the third largest in the Asian region after
Australia and China.
 The Indian biotechnology sector has excellent potential and is expected
to touch five billion-dollar mark by 2010.
 The biotechnology sector in India is growing rapidly at a rate of over 40
percent annually. India is the largest producer of recombinant
Hepatitis B vaccine in the world.
 India occupies a significant position in the world pharma market, 8% by
volume
 (fourth largest in the world) and 1% by value. The pharma industry
ranks 17th in
 terms of export value. India accounts for 22% of the global generics
market

 SOCIAL
 Biopharmaceuticals: This constitutes the largest segment of the Indian
biotech industry both in terms of domestic and export revenues.
About 70 percent of the domestic biotech industry comprises of the
Biopharma sector. Of the total 325 biotechnology companies in India,
more than 40 percent are in the biopharma sector. Vaccines,
therapeutics and diagnostics fall into this category.
 BioServices: The Bioservices market is the second largest sector of the
Indian Biotechnology Industry. The market’s growth can be attributed
to the fact that India has become a popular destination for clinical
trial, contract research and manufacturing activities.
 Agricultural Biotechnology: This segment can be segmented into
Hybrid seeds and transgenic crops, Biopesticides and Biofertilizers.
Genetically modified cotton or commonly known as Bt cotton
constitutes approximately 77 percent of the revenue of this sector
whereas Biopesticides and biofertilizers together account only for 23
percent of the revenues garnered by agricultural biotechnology.
CONTD…
 BioInformatics / BioIT: This sector deals with the creation
and maintenance of extensive electronic databases on
various biological systems and is probably the smallest
part of the current domestic biotechnology industry.
However, India is known for its strong IT base and it is
due to this that India is sure to become a leading
destination for work in the bioinformatics arena.
 BioIndustrial: This industry predominantly consists of
enzyme manufacturing and marketing companies. These
enzymes are used in industries such as detergents, textiles,
food, leather, paper and pharmaceuticals. This generates 6
percent of the revenues of the biotechnology industry.


TECHNOLOGY
Biotechnology is expected to offer investment opportunities of Rs. 9-10 billion In


the next 5 years and the growth is expected in the following areas:
 Vaccines: Vaccines and recombinant therapeutics are the leading sectors driving
the growth of the biotechnology industry in India. It is estimated to reach $20
billion in 2012.
 Bioactive Therapeutic Proteins: Production of proteins and antibodies and
fabrication of diagnostic protein chips would be a promising area for
investment.
 Stem cell research, cell engineering and cell based therapeutics could be another
area where India could cash in its expertise. Up to 25% growth is expected in
this field.
 Agriculture sector: India has the potential to become a major producer of
transgenic rice and several genetically modified (GM) or engineered
vegetables by 2010.There is an increasing use of molecular markers in crop
breeding and a growing realization that some of these new technologies
could lead to future growth in the productivity and quality of crops such as
rice, wheat, eggplant (brinjal), tomato and lady’s finger.


Financial analysis
 Grew threefold in just five years to report revenues of US$ 3
billion in 2009-10
 Rise of 17 per cent over the previous year, according to the
eighth annual survey conducted by the Association of
Biotechnology-Led Enterprises (ABLE) and a monthly
journal.
 The biopharma sector contributed nearly three-fifth to the
industry's revenues at US$ 1.9 billion, a rise of 12 per cent,
followed by bioservices at US$ 573 million and bioagri at
US$ 420.4 million. The remaining revenue came from the
bioindustrials US$ 122.5 million and bioinformatics US$
50.2 million segments.
CONTD…
 Biopharma and bioservices sectors contributed 63 per cent and 33
per cent, respectively, to the total biotech exports. The
bioagriculture, bioindustrials and bioinformatics sectors remained
focussed on domestic operations, bringing in nearly 90 per cent of
their revenues from India
 Biocon, which has topped the list of biotech companies in India in
the ABLE survey, India is looking forward to achieve US$ 5
billion in revenue this fiscal (2010-11).
 According to a joint study by an industry body and Ernst and Young
(E&Y) released in August 2009, the industry in India have grown
by 116 per cent during June 2009 and August 2010.
 The country moved from rank 18 to 12 across the 60 most active
countries in 2010.

TOP BIOTECH INDUSTRIES
 Biocon
 Serum Institute of India
 Panacea Biotec
 Nicholas Piramal
 Wockhadrt Limited
 GlaxoSmithKline
 Bharat Serum
 Krebs Biochemicals and Industries Limited
 Zydus Cadila
 Indian Immunologicals

BIOCON
 Biocon was started on 29th November, 1978 in Bangalore.
 Biocon’s Founding Day - the start of a biorevolution in India.
 Biocon India is incorporated as a joint venture between Biocon
Biochemicals Ltd. of Ireland and an Indian entrepreneur,
Ms.Kiran Mazumdar-Shaw
 It has evolved from an enzyme-manufacturing company into a
fully integrated biopharmaceutical enterprise.
 Biocon delivers products and solutions to partners and
customers in approximately 75 countries across the globe.
 Biocon is ranked among the top 20 global biotechnology
companies and the 7th largest biotech employer in the world.

CONTD…
 Its mission is to be an integrated biotechnology enterprise of
global distinction.
 Revenue increased 53% from Rs. 10,902 million to Rs. 16,732
million.
 Received ISO 9001 accreditation in 1993 and recertification
for ISO 9001:2008, ISO 14001:2004 certification & OHSAS
18001:2007 certification.
 AWARDS
 Padmashri in 1989 and Padmabhushan in 2005 for pioneering
biotechnology in India.
 Named among TIME magazine’s 100 most influential people in
the world in 2010



CONTD…


 India's No. 1 biotech company with a global ranking of 16 in

2004.
 Biocon wins prestigious BioSingapore Asia Pacific
Biotechnology Award for Best Listed Company in 2009.
 Biocon wins Bio-Excellence Award for Outstanding
Achievement in the Healthcare Sector.
 Biocon among Top 20 Indian companies in Forbes ‘Best Under
A Billion’ list.




SERUM INSTITUTE OF INDIA
 Serum Institute of India was founded in 1966 in Pune.
 SII belongs to the Poonawalla Group.
 SII is basically an organisation concentrating on vaccines and
other biologicals.
 SII aims to manufacture life-saving immuno-biologicals, which
were in shortage in the country and imported at high prices.
 World's largest producer of Measles and DTP group of vaccines.
 Dr.Cyrus S. Poonawalla, Chairman & MD, SII.
 Two out of every three children immunized in the world is
vaccinated by a vaccine manufactured by Serum Institute.

CONTD…
 SII’s range of products have been used in 140 countries
across the globe.
 Serum Institute went on to launch, Anti-Snake Venom
Serum, Measles, Mumps and Rubella Virus Vaccine,
and several other products that attest to its seriousness
of purpose.
 SII eliminated India’s dependence on imports for several
product lines
 The largest supplier for the Government’s Expanded
Programme of Immunization.
 Nurtured a core group of Biotechnology scientists, which
has gained official recognition in International scientific
forums.


CONTD…
 AWARDS
 The only private sector manufacturer of vaccines from a
developing nation to be invited to Geneva for WHO’s
programme of ‘Children’s Vaccine Initiative’.
 Certificate of Merit awarded by CHEMEXCIL, Mumbai, for
outstanding export performance in 1994, 1995, 1996, 1997.
 Vikas Bharati Award received in 1997 from International Council
for Business Promotion for outstanding achievements and
contribution in the field.
 The Ernst and Young (E&Y) Award for Health and Life Sciences,
2007 being awarded to Dr Cyrus Poonawalla.
 Serum Institute of India have recently set up Serum Bio Pharma
Park, India's first biotech Special Economic Zone (SEZ).


GLAXOSMITHKLINE
 GlaxoSmithKline is formed through the merger of Glaxo
Wellcome and SmithKline Beecham in 2000.
 Sir Christopher Gent is the Chairman of GSK.
 GSK moves to its new UK headquarters in Brentford, West
London.
 Mission
üGrow a diversified global business.
üDeliver more products of value.
üSimplify the operating model.
 They produce prescription medicines, vaccines and
healthcare products.


CONTD…
 GSK works as a partner with under-served communities in the
developed and developing world supporting programmes that
are innovative, sustainable and bring real benefit to these
communities.
 GSK’s work with communities has been recognised by Business
in the Community (BITC) with a CommunityMark, given to
companies which are highly involved in community works.
 GSK is the first manufacturing company to receive the award.
 GSK identified that R&D was best done in smaller more
productive units and introduced Centres of Excellence for Drug
Discovery (CEDDs), Pioneers in the Quest for New Medicines.
 We delivered 1.4 billion vaccine doses in 2009, of which nearly 1
billion were shipped for use in developing countries.


THANK YOU